SE0103839D0 - Pharmaceutical formulation & product - Google Patents

Pharmaceutical formulation & product

Info

Publication number
SE0103839D0
SE0103839D0 SE0103839A SE0103839A SE0103839D0 SE 0103839 D0 SE0103839 D0 SE 0103839D0 SE 0103839 A SE0103839 A SE 0103839A SE 0103839 A SE0103839 A SE 0103839A SE 0103839 D0 SE0103839 D0 SE 0103839D0
Authority
SE
Sweden
Prior art keywords
alpha
product
drug
patient
methylpropiono
Prior art date
Application number
SE0103839A
Other languages
Swedish (sv)
Inventor
Nicola Bateman
Julie Cahill
Neill Carman
Ian Cockshott
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103839A priority Critical patent/SE0103839D0/en
Publication of SE0103839D0 publication Critical patent/SE0103839D0/en
Priority to TW091132270A priority patent/TW200406200A/en
Priority to UY27539A priority patent/UY27539A1/en
Priority to MXPA04004591A priority patent/MXPA04004591A/en
Priority to ES02779684T priority patent/ES2278063T3/en
Priority to BR0214135-3A priority patent/BR0214135A/en
Priority to IL16190202A priority patent/IL161902A0/en
Priority to DE60217390T priority patent/DE60217390T2/en
Priority to ARP020104386A priority patent/AR037390A1/en
Priority to AT02779684T priority patent/ATE350016T1/en
Priority to JP2003545287A priority patent/JP2005514355A/en
Priority to EP02779684A priority patent/EP1448168B1/en
Priority to US10/495,012 priority patent/US20050038111A1/en
Priority to CA002466986A priority patent/CA2466986A1/en
Priority to KR1020047007359A priority patent/KR20050044468A/en
Priority to PCT/GB2002/005159 priority patent/WO2003043606A1/en
Priority to AU2002343024A priority patent/AU2002343024A1/en
Priority to CNA028272277A priority patent/CN1615122A/en
Priority to ZA200403689A priority patent/ZA200403689B/en
Priority to NO20042502A priority patent/NO20042502L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical product for administration to a patient, the product comprising 4'-cyano-alpha',alpha',alpha'-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide, or a pharmaceutically acceptable salt or solvate thereof, in solid dispersion with an enteric polymer having a pKa from 3 to 6, the product further comprising an anti-oestrogen (eg, tamoxifen citrate) and/or an aromatase inhibitor (eg, anastrozole). The invention also relates to a pharmaceutical dose of the drug and anti-oestrogen/aromatase inhibitor provided by such a formulation. An advantage is the treating and/or preventing of at least one side effect selected from gynaecomastia, breast tenderness, hot flushes, impotence and reduction in libido, while increasing the bioavailability of the drug; reducing inter-patient variability in plasma concentrations of the 4'-cyano-alpha',alpha',alpha'-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide; enhancing the storage stability of the drug; and/or treating and/or reducing the risk of prostate cancer in a patient.
SE0103839A 2001-11-16 2001-11-16 Pharmaceutical formulation & product SE0103839D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE0103839A SE0103839D0 (en) 2001-11-16 2001-11-16 Pharmaceutical formulation & product
TW091132270A TW200406200A (en) 2001-11-16 2002-10-31 Pharmaceutical formulation
UY27539A UY27539A1 (en) 2001-11-16 2002-11-13 PHARMACEUTICAL FORMULATION
CNA028272277A CN1615122A (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
ARP020104386A AR037390A1 (en) 2001-11-16 2002-11-14 PHARMACEUTICAL FORMULATION
US10/495,012 US20050038111A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
BR0214135-3A BR0214135A (en) 2001-11-16 2002-11-14 Pharmaceutical product, pharmaceutical dose, uses of an anti-estrogen and aromatase inhibitor and 4'-cyano-alpha ', alpha, alpha'-trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropiono- m-toluidide or a pharmaceutically acceptable salt or solvate thereof, and method for treating prostate cancer and / or reducing the risk of prostate cancer in a patient.
IL16190202A IL161902A0 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
DE60217390T DE60217390T2 (en) 2001-11-16 2002-11-14 BICALUTAMIDE-CONTAINING PHARMACEUTICAL COMPOSITION
MXPA04004591A MXPA04004591A (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide.
AT02779684T ATE350016T1 (en) 2001-11-16 2002-11-14 PHARMACEUTICAL COMPOSITION CONTAINING BICALUTAMID
JP2003545287A JP2005514355A (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
EP02779684A EP1448168B1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
ES02779684T ES2278063T3 (en) 2001-11-16 2002-11-14 PHARMACEUTICAL FORMULATION UNDERSTANDING BICALUTAMIDA.
CA002466986A CA2466986A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
KR1020047007359A KR20050044468A (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
PCT/GB2002/005159 WO2003043606A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
AU2002343024A AU2002343024A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
ZA200403689A ZA200403689B (en) 2001-11-16 2004-05-13 Pharmaceutical formulation comprising bicalutamide
NO20042502A NO20042502L (en) 2001-11-16 2004-06-15 Pharmaceutical formulation comprising bicalutamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103839A SE0103839D0 (en) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Publications (1)

Publication Number Publication Date
SE0103839D0 true SE0103839D0 (en) 2001-11-16

Family

ID=20286023

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103839A SE0103839D0 (en) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Country Status (20)

Country Link
US (1) US20050038111A1 (en)
EP (1) EP1448168B1 (en)
JP (1) JP2005514355A (en)
KR (1) KR20050044468A (en)
CN (1) CN1615122A (en)
AR (1) AR037390A1 (en)
AT (1) ATE350016T1 (en)
AU (1) AU2002343024A1 (en)
BR (1) BR0214135A (en)
CA (1) CA2466986A1 (en)
DE (1) DE60217390T2 (en)
ES (1) ES2278063T3 (en)
IL (1) IL161902A0 (en)
MX (1) MXPA04004591A (en)
NO (1) NO20042502L (en)
SE (1) SE0103839D0 (en)
TW (1) TW200406200A (en)
UY (1) UY27539A1 (en)
WO (1) WO2003043606A1 (en)
ZA (1) ZA200403689B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60206889T2 (en) * 2001-02-27 2006-07-27 Astrazeneca Ab PHARMACEUTICAL FORMULATION CONTAINING BICALUTAMIDE
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7226622B2 (en) * 2003-09-18 2007-06-05 Boston Scientific Scimed, Inc. Chemoablation of tissue using biodegradable, solid salt dosage forms
NZ548670A (en) * 2004-01-28 2010-05-28 Androscience Corp Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
WO2006024944A2 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2006090129A2 (en) * 2005-02-23 2006-08-31 Astrazeneca Ab Bicalutamide for delivering increasing steady state plasma levels
US20080177109A1 (en) * 2005-03-29 2008-07-24 Usv Limited Novel Process for Preparation of Bicalutamide
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
WO2009105264A1 (en) * 2008-02-21 2009-08-27 Iris International Inc. Method for early determination of recurrence after therapy for prostate cancer
ES2855426T3 (en) * 2008-09-17 2021-09-23 Mylan Inc Granules, their preparation process and pharmaceutical products that contain them
UA117353C2 (en) 2012-09-11 2018-07-25 Медівейшн Простейт Терап'Ютікс Ллс Formulations of enzalutamide
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN107049972A (en) * 2017-03-17 2017-08-18 万特制药(海南)有限公司 A kind of dispersible tablet containing Letrozole solid dispersions and its preparation technology

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121152A1 (en) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "USE OF THE COMBINATION OF AN AROMATASE INHIBITOR WITH AN ANTIANDROGEN FOR PROPHYLAXIS AND THERAPY OF PROSTATE HYPERPLASIA"
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
WO1995019770A1 (en) * 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating

Also Published As

Publication number Publication date
CN1615122A (en) 2005-05-11
ZA200403689B (en) 2006-06-28
TW200406200A (en) 2004-05-01
KR20050044468A (en) 2005-05-12
AU2002343024A1 (en) 2003-06-10
MXPA04004591A (en) 2004-08-13
US20050038111A1 (en) 2005-02-17
IL161902A0 (en) 2005-11-20
BR0214135A (en) 2004-10-13
DE60217390T2 (en) 2007-11-15
WO2003043606A1 (en) 2003-05-30
AR037390A1 (en) 2004-11-10
EP1448168B1 (en) 2007-01-03
DE60217390D1 (en) 2007-02-15
EP1448168A1 (en) 2004-08-25
ES2278063T3 (en) 2007-08-01
CA2466986A1 (en) 2003-05-30
JP2005514355A (en) 2005-05-19
UY27539A1 (en) 2003-07-31
NO20042502L (en) 2004-08-09
ATE350016T1 (en) 2007-01-15

Similar Documents

Publication Publication Date Title
SE0103839D0 (en) Pharmaceutical formulation & product
DE602004017194D1 (en) PYRIDYLPYRROL DERIVATIVES AS ACTIVE KINASE INHIBITORS
IS6970A (en) Solid formulation comprising 4-cyano-trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropion-m-toluidide and PVP
CR8352A (en) PHARMACEUTICAL FORMULATIONS, PROCEDURES AND DOSAGE GUIDELINES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES
BR0110877A (en) Methods of treating primary cancer, increasing the dosage of a topoisomerase inhibitor, reducing or preventing an adverse effect associated with chemotherapy and radiation therapy, increasing the therapeutic efficacy of a topoisomerase inhibitor, and protecting a cancer patient from adverse effects associated with administration of an anti-cancer drug, pharmaceutical composition, dosage form, and kit for use in cancer treatment
MXPA06000302A (en) Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
UY27186A1 (en) PHARMACEUTICAL FORMULATION
WO2005065646A3 (en) Novel drug compositions and dosage forms
ATE396986T1 (en) PYRIMIDYLPYRROLE DERIVATIVES THAT ACTION AS KINASE INHIBITORS
EA200501105A1 (en) PHARMACEUTICAL COMPOSITION
SE9901573D0 (en) New compounds
SE0103424D0 (en) Pharmaceutical formulation
ATE341319T1 (en) PREPARATIONS CONTAINING ESMOLOL
ATE442158T1 (en) ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITIONS HAVING A DELIVERY AGENT IN MICRONIZED FORM
SE0103838D0 (en) Pharmaceutical formulation & product
MXPA06007510A (en) Novel drug compositions and dosage forms of topiramate.
PE20031047A1 (en) TREATMENT OF POST-MENOPAUSAL PATIENTS IN PATIENTS WITH BREAST CANCER
SE0102887D0 (en) New formulation
MX2009006873A (en) Disintegration promoters in solid dose wet granulation formulations.
SE0102886D0 (en) New formulation
Thomas Considering Bio/Pharma Reformulation Strategies
JP2017514834A5 (en)
SE0102888D0 (en) New formulation
WO2001035946A3 (en) Intranasal administration of raloxifene and tamoxifen